Virginia Commonwealth University

Virginia Commonwealth University

Virginia Commonwealth University

Date Founded



910 West Franklin Street, Box 842512, Richmond, Virginia, 23284-2512, United States

Charitable Causes

Higher Education & Universities

Company Description

Virginia Commonwealth University (VCU) in Richmond, Virginia, is a high-ranking research university that offers comprehensive academics in the liberal and fine arts, sciences and professional fields. VCU's campus life is also comprehensive and offers many opportunities. Virginia Commonwealth University has more than 10 distinctive schools that award bachelor's, master's and doctoral degrees. Students may earn undergraduate degrees in such fields as: * African American Studies * Art Education * Bioinformatics * Business * Film and Photography * Nursing * Religious Studies Virginia Commonwealth's diverse graduate programs include: * Clinical Psychology * Creative Writing * Engineering * Physical Therapy * Social Work * Theatre Virginia Commonwealth has consistently received high rankings. U.S. News and World Report rated it as a Tier 1 University and ranked the School of the Arts as one of the best nationally. Other programs that have received high rankings are business and education. Student life activities also abound and include more than 200 organizations, several student publications and a student radio station. VCU also hosts one of the nation's largest university film festivals.

Contact Data
Trying to get in touch with decision makers at Virginia Commonwealth University? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees



Senior Executive Director Innovation Gateway

Senior Executive Director Research Information Systems

Board of Visitors

President & Chief Executive Officer at Goodwill of North Georgia, Inc.

Limited Partner at Lead Edge Capital Management LLC

Chief Executive Officer at Pam El Consulting

Managing Partner at Tuckahoe Holdings LLC

Former Doctor at Petersburg Eye Center

President at Sentara Albemarle Medical Center

President at TowneBank - Williamsburg Branch

Former Chief Executive Officer & Chairman of the Board at S&K Famous Brands, Inc.

Managing Director at Hunton Andrews Kurth LLP

Founding Principal at Mozaic Strategies

Distinguished Alumni
Jonathan B. Perlin is now Chief Medical Officer at HCA Healthcare, Inc.
Robert Daniel Oshinskie is now Chief Investment Officer, US Equities at Rothschild & Co. Asset Management US, Inc.
Jeff Gronning is now Executive Vice President & Chief Investment Officer at Columbia Property Trust, Inc.
Paths to Virginia Commonwealth University
Potential Connections via
Relationship Science
Virginia Commonwealth University
Recent Transactions
Details Hidden

Optima Health Plan, Sentara Healthcare purchase Virginia Premier Health Plan, Inc. from Virginia Commonwealth University


DURECT Corporation is a specialty pharmaceutical company focused on the development of pharmaceutical systems based on its proprietary drug delivery platform technologies to treat chronic debilitating diseases and enable biotechnology products. These platform technologies include the SABER® Delivery System (a patented and versatile depot injectable useful for proteins, peptides and small molecule delivery), the ORADUR® sustained release oral gel-cap technology (an oral sustained release technology with several potential abuse deterrent properties), the TRANSDUR® transdermal patch technology, the DURIN® Biodegradable Implant (drug-loaded implant system) and the MICRODUR™ Biodegradable Microparticulates (microspheres injectable system). DURECT also partners with pharmaceutical and biotechnology companies to develop and commercialize proprietary and enhanced pharmaceutical products based on its technologies. DURECT has seven disclosed on-going development programs of which six are in collaboration with pharmaceutical partners. DURECT’s strategy is to capitalize on the wealth of opportunities afforded by our proprietary platform technologies in three ways: To internally develop promising products based on our technologies To partner some of our product opportunities with development and/or commercialization partners at appropriate stages along the development timelines; and To make our technologies, along with our pre-clinical and clinical development expertise available to partners with the desire to develop proprietary extended or controlled release formulations of a wide range of molecules. The statements within the DURECT Corporation website, and affiliated websites, relating to DURECT's products in development, technology attributes or capabilities, product development plans, development timelines, expected product or technology benefits or potential product markets involve risks and uncertainties that could cause actual results to differ materially from those in such forward looking statements. Potential risks and uncertainties include, but are not limited to, our ability to develop and commercialize our products, our ability to complete successful clinical trials, our ability to obtain product approvals from regulatory agencies, marketplace acceptance of our products, our ability to successfully manufacture our products, our reliance on sole or limited suppliers, our ability to obtain adequate reimbursement from third-party payors and the introduction of competitive products by other companies, our ability to gain access to proprietary technology and drugs, our ability to enter into development or commercialization agreements with other life sciences companies, our ability to manage our growth and costs and relationships with third parties and finance our activities and operations. Further information regarding these and other risks is included in the company's S-1 registration statement, quarterly reports on Form 10-Q and annual report on Form 10-K, as filed with the SEC. Copies of these documents are available on request from the Investor Relations Department of DURECT

Enzo Biochem, Inc. engages in the development, manufacture and sale of technology solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians globally. It operates through the following segments: Enzo Clinical Laboratory Services, Enzo Life Sciences Products, and Enzo Therapeutics. The Enzo Clinical Laboratory Services segment includes clinical reference laboratory providing a wide range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. The Enzo Life Sciences Products segment manufactures, develops and markets products and tools for clinical research, drug development and bioscience research customers worldwide. The Enzo Therapeutics segment develops multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases, many of which are derived from the pioneering work of Enzo Life Sciences. The company was founded by Elazar Rabbani, Barry W. Weiner and Shahram K. Rabbani in 1976 and is headquartered in New York, NY.

National Disease Research Interchange provides human bio specimens to scientists in academic, corporate and independent research organizations throughout the world. It offers customized tissue procurement, with acquisition and processing tailored to the specific requirements of protocol. The company was founded by Leatrice Ducat in 1980 and is headquartered in Philadelphia, PA.

Non-Profit Donations & Grants
Non-Profit Donations & Grants Received
Segra IT Consulting & Services | Norfolk, VA

Segra lead with technology backed by a solid commitment to our customers. Following a successful merger of Lumos Networks and Spirit Communications, we are now proud to offer one of the largest and most advanced infrastructure networks in the eastern US. Our state-of-the-art fiber network covers over 21,000 miles that connects more than 9,000 on-net locations and 44 data centers throughout the Mid-Atlantic and Southeast and is delivered with our industry-leading service and reliability.

SP Plus Corp. Other Business & Consulting Services | Chicago, IL

SP Plus Corp. provides professional parking, ground transportation, facility maintenance, security, event logistics, and baggage handling and related services to commercial, institutional, municipal and aviation clients. It also provides a wide range of event logistics services. The firm operates through the following segments: Commercial, Aviation, and Other. The Commercial segment encompasses services in healthcare facilities, municipalities including meter revenue collection and enforcement services, government facilities, hotels, commercial real estate, residential communities, retail, colleges and universities, as well as ancillary services. The Aviation segment encompasses services in aviation, as well as ancillary services, which include shuttle and ground transportation services, valet services, baggage handling, baggage repair and replacement, remote air check-in services, wheelchair assist services and other services. The company was founded in 1929 and is headquartered in Chicago, IL.

Awards & Honors
Rank #327
The Chronicle of Philanthropy - Philanthropy 400
Rank #248
The Chronicle of Philanthropy - Philanthropy 400
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Virginia Commonwealth University. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Virginia Commonwealth University's profile does not indicate a business or promotional relationship of any kind between RelSci and Virginia Commonwealth University.